Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge by Drew, S. C. et al.
Copper-mediated Amyloid- Toxicity Is Associated with an
Intermolecular Histidine Bridge*□S
Received for publication, January 17, 2006, and in revised form, March 24, 2006 Published, JBC Papers in Press, April 6, 2006, DOI 10.1074/jbc.M600417200
David P. Smith‡§1, Danielle G. Smith‡§, Cyril C. Curtain‡§¶, John F. Boas¶, John R. Pilbrow¶, Giuseppe D. Ciccotosto‡§,
Tong-Lay Lau‡, Deborah J. Tew‡§, Keyla Perez‡§, John D. Wade**, Ashley I. Bush§‡‡2, Simon C. Drew§§,
Frances Separovic, Colin L. Masters‡§2, Roberto Cappai‡§¶¶2, and Kevin J. Barnham‡§2,3
From the ‡Department of Pathology, ¶¶Centre for Neuroscience, and School of Chemistry, University of Melbourne, Victoria 3010,
Australia, the §Mental Health Research Institute of Victoria, Victoria 3010, Australia, the ¶School of Physics, Monash University,
Victoria 3800, Australia, the **Howard Florey Institute of Medical Research, Victoria 3010, Australia, the ‡‡Laboratory for
Oxidation Biology, Genetics, and Aging Research Unit, Massachusetts General Hospital, HarvardMedical School,
Charlestown, Massachusetts 02129, and the §§Centre for Magnetic Resonance and Centre for Metals in Biology,
University of Queensland, Queensland 4072, Australia
Amyloid- peptide (A) is pivotal to the pathogenesis of Alzhei-
mer disease. Here we report the formation of a toxic A-Cu2 com-
plex formed via a histidine-bridged dimer, as observed at Cu2/
peptide ratios of >0.6:1 by EPR spectroscopy. The toxicity of the
A-Cu2 complex to cultured primary cortical neurons was atten-
uated when either the- or -nitrogen of the imidazole side chains
of His were methylated, thereby inhibiting formation of the His
bridge. Toxicity did not correlatewith the ability to formamyloid or
perturb the acyl-chain region of a lipid membrane as measured by
diphenyl-1,3,5-hexatriene anisotropy, but did correlate with lipid
peroxidation and dityrosine formation. 31P magic angle spinning
solid-state NMR showed that A and A-Cu2 complexes inter-
acted at the surface of a lipid membrane. These findings indicate
that the generation of theA toxic species ismodulated by theCu2
concentration and the ability to form an intermolecular His bridge.
The interaction of metals with the amyloid- peptide (A)4 plays a
pivotal role in the pathogenesis of Alzheimer disease (AD). Transition
metals, such as copper (Cu2), zinc (Zn2), and iron (Fe3), are enriched in
A plaques (1), and the A peptide possesses both high and low affinity
Cu2 and Zn2 binding sites in vitro. These interactions with Cu2,
Zn2, and to a lesser extent Fe3 have been reported to control the
aggregation state of A. Moreover, the A-Cu2 complexes are redox-
active, suggesting that the oxidative stress observed in AD patients is
related to the production of reactive oxygen species (ROS) by metal-
bound forms of A and may be central to the pathological mechanism
of AD (reviewed by Bush (1)).
The coordination environment of Cu2 bound to A has been stud-
ied by EPR, Raman, and NMR spectroscopies. The consensus is that the
coordination of Cu2 to A is via the three His residues His6, His13, and
His14 and an as yet undefined fourth ligand; options put forward include
tyrosine (Tyr10) (2–6), the N-terminal nitrogen (7), or an as yet uniden-
tified carboxylate side chain (8, 9) (Fig. 1a). Recently, Glu11 has been
identified as providing the carboxylate side chainwhenZn2 is bound to
A 1–16 (10). The EPR studies of Curtain et al. (2) showed that in the
pH range 6.0 to 7.5 in PBS, an increase in the Cu2/peptide molar ratio
above 0.3:1 broadened the mononuclear Cu2 spectrum observed at
low ratios. At Cu2/peptidemolar ratios greater than 0.6:1, a distinctive
broad resonance developed near g 2. This broad resonancewas attrib-
uted to exchange interactions between two Cu2 ions6 Å apart, with
the second Cu2 ion being coordinated to A in a cooperative manner
via a His bridge (Fig. 1b), similar to that observed byOhtsu et al. (11) for
Cu2 bridge imidizolate complexes. Here we report the first observa-
tion of resonances at g  4 in the EPR spectra of A-Cu2 peptides,
where the broad g  2 line is also observed. Such EPR spectra are
diagnostic for the existence of binuclear Cu2 centers where the Cu2
ions are coupled by dipolar interactions; simulations presented here
demonstrate that these atoms are 6.2 0.2 Å apart (12). This distance is
consistent with a His bridge between the Cu2 atoms. To further the
understanding of the role played by the His bridge and A-lipid inter-
actions in the neurotoxicity of A, we examine the toxic mechanism of
both metal-free and Cu2-bound forms of the A peptide.
The link between His bridge formation and neurotoxicity was
explored through experiments using A 1-42 peptides modified by the
methylation of the His residues at either the - or -nitrogen of the
imidazole side chain (Fig. 1c). Correspondingly modified A 1-40 has
been shown to be nontoxic, despite being redox-active in a manner
similar to the wild type (WT) peptide (4). This lack of toxicity has been
attributed to these peptides being unable to bind to cell surface mem-
branes, congruentwith the notion that A-lipidmembrane interactions
are central to the cause of neurotoxicity in AD (13–17). Here we
describe the Cu2 coordination, lipid interactions, and aggregation
properties of both the neurotoxic WT A 1-42 peptide and A 1-42
where the His residues have been methylated at either the - or -
nitrogen of the imidazole side chain. The Cu2-bound WT A 1-42
peptide was shown to be significantly more toxic, as monitored by the
viability of primary cortical neurons, under conditions in which the His
bridge was formed. Perturbation of this metal coordination mode leads
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to a loss in toxicity even in the presence of Cu2. We also show that
toxicity correlates with the ability of the peptides to form dityrosine and
induce lipid peroxidation. Toxicity displays a negative correlation with
the formation of amyloid material and the ability to perturb the acyl-
chain region of lipid bilayer. These results show that the ability to form
a Cu2-linked His bridge dimer, resulting ultimately in lipid peroxida-
tion, is central to the metal-meditated toxicity of A.
EXPERIMENTAL PROCEDURES
All reagents were purchased from Sigma unless otherwise stated.
Peptide Synthesis—The uncommonNim-protected amino acids, Fmoc-
L-His(N-1-Me)-OH (His--Me) and Fmoc-L-His(N-3-Me)-OH (His--
Me),werepurchased fromBachem(Bubendorf, Switzerland); allwereused
without further purification. All modified peptides were synthesized
according to methods outlined previously (18). Due to the large degree
of similarity between the peptides, large batches of resins were pre-
pared and split at appropriate points in the synthetic pathway such
that each peptide was prepared on a scale of 0.03 mmol. WT A 1-42
was purchased from the W. M. Keck Laboratory (Yale University,
New Haven, CT).
Peptide and Aggregate Preparation—PBS is defined as 10mM sodium
phosphate, 150 mMNaCl at pH 7.4. Cu2 was present as a solution of 1
part CuCl2 to 6 parts glycine. The addition of a glycine counterion was
essential in order to prevent the formation of insoluble phosphate-metal
complexes. A 25 mM stock solution was made and diluted in deionized
water to the desired concentration as required. Peptide working solu-
tions were prepared by taking a known amount of A 1-42 and then
dissolving it in 1,1,1,3,3,3-hexafluoro-2-isopropanol (HFIP). The pep-
tide was incubated at 25 °C for 1 h to remove any preformed structure.
Known amounts of peptide were then aliquoted out, and HFIP was
removed by evaporation. The resulting peptide film was stored at
80 °C until required. The filmwas dissolved in 20mMNaOH and then
diluted out in deionized water and 10 PBS at a v/v/v ratio of 2:7:1. All
solutions were sonicated in a water bath for 10 min and centrifuged for
10min at 4 °C at high speed before the addition of 10 PBS. The super-
natant was kept on ice for immediate use. The absorbance value at 214
nm was measured, and the concentration of the peptides was deter-
mined using a molar extinction coefficient value of 75,887 liters/mol/
cm, adjusting to the required concentration with buffer A. CuCl2/Gly
was added to the required concentration from a 25 mM stock. Samples
were used immediately or incubated at 37 °C with agitation at 200 rpm
for either 2 or 24 h.
EPR Spectroscopy—Continuous wave EPR spectra were obtained
with Bruker ESP380E FT/CW and ECS106 X-band spectrometers.
Temperatures around 120 K in both were achieved with a Bruker nitro-
gen gas flow insert in the standard rectangular TE012 cavity. Spectra
acquired at 2.5 K using the ESP380E were achieved using an Oxford
Instruments CF935 cryostat with an ER4118 cylindrical cavity insert.
The microwave frequency was measured with an EIP microwave 548A
frequency counter, and the g factors were determined with reference to
the F line in CaO (19). Spectrum simulations were performed with the
SOPHE software (version 1.1.4) described by Hanson et al. (20). For the
EPR measurements, the chloride of 99.99% pure 65Cu (Cambridge Iso-
topes) was used. The peptides were dissolved from an HFIP-treated
stock to 100 M in deionized water, and 65CuCl2 to the desired Cu2/
peptide molar ratio was added immediately from a 2.0 mM stock solu-
tion via a glass microsyringe. The pHwas then adjusted to 7.4 by adding
concentrated PBS or ethylmorpholine buffer, and after mixing, samples
were rapidly transferred to Wilmad “Suprasil” EPR tubes and frozen
immediately. Before and after the EPR spectroscopy, metal concentra-
tions weremeasured by inductively coupled plasmamass spectrometry,
and peptide concentrations were determined by quantitative amino
acid analysis.
High Performance Immobilized Metal Ion Chromatography—All so-
lutions were delivered to the column at a flow rate of 1.5 ml/min. The
high performance immobilized metal ion chromatography column
(Amersham Biosciences) was swollen in PBS (pH 7.4), washed in EDTA
(50 mM) to remove trace metals, and then washed with deionized H2O.
The column was charged with Cu2 by injecting 2 ml of 0.1 M CuCl2/
glycine(1:6). The excessmetal was removed bywashing the columnwith
deionized H2O. The column was then re-equilibrated in PBS (15 ml).
The peptides were prepared at 1 mM in 10% 2,2,2-trifluoroethanol/
PBS, and 5 l was injected onto the column. The peptides were eluted
using either a pH gradient (7.4–2.5) generated by a linear increase
(0–100%) in PBS at pH 2.5 or an imidazole gradient (0–100% 500 mM
imidazole in PBS at pH 7.4).
Primary Neuronal Cultures—Cortical neuronal cultures were prepared
as described previously (21). Briefly, embryonic day 14 BL6Jx129sv mouse
cortices were removed, dissected free of meninges, and dissociated in
0.025% (w/v) trypsin in Krebs buffer. The dissociated cells were triturated
using a filter-plugged fine pipette tip, pelleted, resuspended in plating
medium (minimum Eagle’s medium, 10% fetal calf serum, 5% horse
serum), and counted. Cortical neuronal cells were plated into poly(L-
lysine)-coated 48-well plates at a density of 125,000 cells/well in plating
medium. All cultures were maintained in an incubator set at 37 °C with
5% CO2. After 2 h, the plating medium was replaced with fresh neuro-
basal medium containing B27 supplements, Geneticin, and 0.5 mM glu-
tamine (all tissue culture reagents were purchased from Invitrogen
unless otherwise stated). This method resulted in cultures highly
enriched for neurons (95% purity) with minimal astrocyte andmicro-
glial content as determined by immunostaining of culture preparations
using specific marker antibodies.
Cell Viability Assay—The neuronal cells were allowed to mature for
6 days in culture before commencing treatment using freshly prepared
serum free neurobasal medium plus B27 supplements minus antioxi-
dants. For the treatment of neuronal cultures, peptide was prepared at
50 M at Cu2/peptide molar ratios of 0:1, 0.1:1, 1:1, and 10:1 and used
immediately. Peptides were diluted to the final concentration of 5M in
neurobasalmedium.Themixtureswere then added to neuronal cells for
96 h. Cell survival was monitored by phase-contrast microscopy, and
cell viability was quantitated using the MTS assay as described previ-
ously (21). Briefly, the medium was replaced with fresh neurobasal
FIGURE 1. Illustration of Cu2 coordination by A. a, N3O coordination about the
Cu2 is supplied by the imidazole nitrogens of the three His side chains (His6, His13, and
His14) and a yet to be identified oxygen atom. b, the imidazole side chain of a His residue
bridging between Cu2 atoms generating A dimer and a metal coordination site sim-
ilar to the active site of SOD 1 (25). c, methylation of the imidazole side chain of His at
either the or position, designed to allow the initial copper binding event to occur but
inhibit the subsequent formation of His-bridged structures.
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medium supplemented with B27 lacking antioxidants, and 10% (v/v)
MTS (Promega,Madison,WI) was added to eachwell and incubated for
3 h at 37 °C in a 5% CO2 incubator. Plates were gently shaken, and a
150-l aliquot from each well was transferred to separate wells of a
96-well plate. The color change of each well was determined by meas-
uring the absorbance at 490 nm using aWallac Victor Multireader, and
background readings of MTS incubated in cell-free medium were sub-
tracted from each value before calculations. The data were normalized
and calculated as a percentage of untreated vehicle control values. Data
are shown as mean S.E. Statistical comparisons between groups were
done using Student’s t test.
Quantification of Aggregate and Fibril Formation—For determina-
tion of fibril growth end points, a discontinuous assay of fibril growth
was used. Peptide samples (20l) were removed from incubation after 2
or 24 h and added to 600l of a 20M thioflavin-T (ThT) solution at pH
7.4 in buffer A. The ThT signal was quantified by averaging the fluores-
cence emission at 480 nm over 10 s when excited at 444 nm using a
PerkinElmer Life Sciences LS55 fluorescence spectrophotometer, slit
widths for excitation of 2.5 nm and emission of 12.5 nm at 37 °C.
Circular Dichroism Spectroscopy—The peptides were prepared as
described above diluting to a final concentration of 20 M in PBS to
achieve a measurable CD signal. Cu2 was titrated into the peptide
preparation at 0.5–2.5 peptide mol eq after diluting the peptide, gently
mixed, and allowed to equilibrate for 15 min at room temperature. Far
UV-CD spectra were collected between 200 and 250 nm at room tem-
perature on a Jasco 810 spectrometer using a quartz cuvette with a 1-cm
path length. Measurements were recorded at 50 nm/min with a band-
width of 1 nm and a response time of 2 s, averaging 10 accumulation
scans per measurement. The spectra were background-subtracted,
smoothed using the Jasco software (version 32) FFT filter function, and
converted to molar ellipticity. All experiments were performed in
triplicate.
Dityrosine Formation—Peptide was prepared at 10 M in the pres-
ence of 250 M H2O2 at Cu2/peptide molar ratios of 1:1. After 24 h of
incubation, the reaction was quenched by the addition of 10 l of 12.5
mM EDTA (final concentration 250 M). Dityrosine content was quan-
tified using a PerkinElmer Life Sciences LS55 fluorescence spectropho-
tometer with an excitation wavelength of 320 nm and scanning the
emission wavelengths from 350 to 500 nm. Maximum light signal was
observed and recorded at 418 nm (22).
Preparation of Large Unilamellar Vesicles—Large unilamellar vesi-
cles (LUVs) were prepared by initially dissolving equal quantities of
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (PC) and 1-palmi-
toyl-2-oleoyl-sn-glycero-3-[phospho-L-serine] (PS) (Avanti Polar Lip-
ids Inc.) in chloroform. The chloroform was evaporated off, and the
lipids were resuspended in buffer A at10 mM and incubated at 37 °C
for 1 hwith agitation at 200 rpm in the presence of glass beads. The lipid
mixture was subjected to five freeze-thaw cycles using liquid nitrogen
and a 37 °C water bath. The sample was then passed through an extruder
apparatus using a 100-nm filter, resulting in a uniform solution of LUVs
with a mean diameter between 120 and 140 nm.
Steady-state Polarization of DPH—Diphenyl-1,3,5-hexatriene (DPH)
was purchased fromMolecular Probes. Briefly, DPHwas dissolved at 10
mM in Me2SO and diluted to 16.6 M in buffer A containing 416 M
LUVs. A 60-l aliquot of this sample wasmixedwith 40l of A 1-42 at
10 M, giving final concentrations of 10 M probe, 250 M LUVs, and 4
M peptide. Samples were then incubated at 37 °C with aggregation at
200 rpm for 20min prior to reading. The dye was excited at 359 nm, and
emissionwas recorded at 430 nm.Anisotropywasmeasured on aVarian
Eclipses spectrophotometer using internal polarizers and calculated by
the equation, r (IvvGIvh)/(Ivv 2GIvh), where Ivv and Ivh are the
fluorescence intensities when the excitation and emission polarizers are
set at v (vertical) and h (horizontal), respectively. The grating factorG
Ihv/Ihh.
Solid-state NMR—Solid-state NMR experiments were conducted on
a Varian Inova 300 spectrometer operating at a resonance frequency of
121.4 MHz for 31P. 31P spectra were acquired at 28 °C, using a Doty
5-mm double resonance NMR probe with a standard Hahn echo and
proton decoupling. Pulse times used were/2 5s pulse with a delay
of 2 s under magic angle spinning of 5 kHz. Typically, 10,000 scans
were acquired, and an exponential line broadening of 10Hzwas applied.
Chemical shift was referenced using 80% phosphoric acid (H3PO4) as 0
ppm for 31P NMR experiments.
Lipid Peroxidation—20M peptide was prepared as above at a Cu2/
peptide molar ratio of 0:1 or 1:1. Samples were incubated for 5 min
before the addition to 50% PC, 50% PS LUVs and ascorbate. Samples
contained a final concentration of 10Mpeptide, 1mMLUV, and 10M
ascorbate andwere incubated for 24 h at 37 °Cwith agitation at 200 rpm.
CQ was prepared in 100% Me2SO and added to final concentrations of
2, 20, and 50 M. The final Me2SO concentration was 1% in all cases.
The level of lipid peroxidation was quantified via a lipid peroxidation
colorimetric assay (Oxford Biomedical Research) as per the manufac-
turer’s instructions.
RESULTS
The His Bridge Dimer as Observed by EPR—Most of the experiments
described below were performed at pH 7.4 in PBS solutions, because
NaCl at a concentration of 0.15 M is part of the physiological milieu.
Under these conditions of pH, peptide concentration, and buffer, the
predominant species observed by EPR depended on the Cu2/peptide
molar ratio. The addition of 65CuCl2 to A 1–16, A 1–28, andWTA
1-42 to give Cu2/peptide molar ratios of 0–0.5:1 gave EPR signals
analogous to that shown in Fig. 2a. These spectra are similar to those
reported previously (2, 3) for low Cu2/peptide ratios and show a spec-
trummainly due tomononuclearCu2 in an approximately axially sym-
metric square planar environment. A simulated spectrum using the
spin-Hamiltonian parameters is given in supplemental Table 1. These
parameters are typical for Cu2 coordinated by 2N2O or 3N1O (23).
At Cu2/peptide molar ratios of above 0.5:1, a significantly different
resonance developed in the g  2 region, as reported previously (2, 4)
and as shown in Fig. 2b. Concurrently, we demonstrate here for the first
time that a resonance also develops at g 4 when very high spectrom-
eter gains are used (Fig. 3). The parallel appearance of the g 2 and g
4 resonances is diagnostic for the existence of a binuclear Cu2 center
(i.e. a pair of Cu2 ions coupled by exchange and/or dipolar interac-
tions) (12). Although the Cu2 hyperfine structure is not well resolved,
its presence is confirmation that the resonance at g 4 is due to a pair
of Cu2 ions and not to a nonspecific aggregate. At Cu2/peptidemolar
ratios of1:1 and greater, another broad resonance developed centered
at g 2.14 (Fig. 2c). No resonance at g 4 appears to be associated with
this new signal, which may be attributed to a number of Cu2 ions
within10 Å of each other but not structurally related. The broken line
spectrum in Fig. 2c represents the simulation of an isotropic resonance
at g 2.14, such as might arise from a number of Cu2 ions within10
Å of each other without a specific geometrical relationship and where
the anisotropic features are averaged by a combination of dipolar and
weak exchange interactions.
Spectra acquired at 2.5 K of A 1–28 (Cu2/peptide molar ratio
1:1) exhibited the same resonances as observed at 120 K at g 2 and
g 4 but with 50 times the intensity, indicating that antiferromagnetic
A-Cu2-mediated Toxicity Requires a His Bridge
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exchange interactions between the Cu2 ions of the dimer must be
		10 cm1. The dimer spectra did not exhibit microwave power satu-
ration up to 25 milliwatts at 2.5 K, indicating the existence of spin-spin
relaxation processes as expected for a coupled system. In contrast, the
mononuclear spectra exhibited power saturation effects above1 mil-
liwatt at 2.5 K. To verify that the g 2 and g 4 spectra were not due to
oxo- or phosphate-bridged binuclear Cu2 centers or to adventitious
Fe3, control spectra were acquired at 120 K of 1.5 mM 65CuCl2 in PBS,
of PBS alone, and of the peptide in PBS prior to the addition of 65CuCl2.
At pH 7.4, no resonances were observed near either g 2 or g 4.
As a comparisonwithWTA 1-42, the spectra ofA 1-42 containing
His--Me orHis--Me at positions 6, 13, and 14were recorded over the
range of Cu2/peptide molar ratios 0.3–1:1. Only mononuclear spectra
were observed, similar to those previously published by Tickler et al. (4).
Therewere no indications of the broad resonance at g 2 characteristic
of the binuclear Cu2 center or for resonances near g  4, even at
spectrometer settings where the g 4 resonances were clearly observed
in the unmodified peptides. Fig. 2d shows the mononuclear spectra
obtained with WT A 1-42 at a Cu2/peptide molar ratio of 0.1:1 and
the similarly mononuclear spectra of His--Me obtained at a Cu2/
peptide molar ratio of 1:1 (Fig. 2e).
High pressure immobilized affinity chromatography was employed
to ascertain if the methylation of the imidazole side chains had a signif-
icant effect on the relative Cu2 binding affinity compared withWTA
1-42. The strength of peptide-metal ion interactions is usually assessed
as a function of the pH required to elute the various peptides from a
Cu2-loaded immobilized metal ion affinity chromatography column.
However, we were unable to elute any of the peptides from the Cu2-
charged immobilized metal ion affinity chromatography column at pH
	2 or by using an imidazole gradient. The peptides could only be eluted
by the addition of EDTA to the eluting buffer, indicating that all pep-
tides had a very high affinity for Cu2.
The effect of buffer conditions on A-Cu2 coordination was inves-
tigated by acquiring spectra of A 1–28 in pH 7.4 ethylmorpholine
buffer over a range of Cu2/peptide molar ratios, recreating the condi-
tions of Syme et al. (7) (supplemental Fig. 1). At Cu2/peptide molar
ratios of 0.1:1 and 1:1, only mononuclear spectra where observed. Spec-
tra in the g 2 region were identical to those reported at Cu2/peptide
ratios of 1:1 by Syme et al. (7). The broad line near g  2 was not
observed, even at Cu2 concentrations and spectrometer settings that
yielded these resonances in PBS. Therefore, A-Cu2 complexes in an
ethylmorpholine buffer do not generate the specific binuclear Cu2
centers observed in PBS at Cu2/peptide molar ratios of1:1.
Observation of the His Bridge as Deduced from EPR Spectro-
scopy—The EPR spectra due to pairs of Cu2 ions separated by dis-
tances of around 3–7 Å were first described 30 years ago (12). These
spectra arise from the exchange and/or dipolar coupling of two Cu2
ions, each with spin S  1⁄2, to give a singlet state (S  0) and a triplet
state (S 1). “Allowed” electron spin transitions within the triplet state,
FIGURE 2.EPR spectra ofA1-28andA1-42at varyingCu2/peptidemolar ratios.
Top, EPR spectra of A 1-28 at Cu2/peptidemolar ratios 0.3:1 (a), 0.6:1 (b), and 1:1 (c) in
PBS, pH 7.4, at 120 K. Spectrometer and settings were as follows: Bruker ESP380E, micro-
wave frequency 9.424GHz,microwavepower 1.05milliwatts,modulation frequency 100
kHz, modulation amplitude 1.0 G, receiver gain 5 104, scan time 84 s, time constant 40
ms, single scan. Broken lines, SOPHE simulations (20) of the predominant species in the
corresponding spectrum. Spin-Hamiltonianparameters are given in supplemental Table
1. Bottom, EPR spectrum of A 1-42 at a Cu2/peptide molar ratio of 0.1:1 (d) compared
with the spectrum of His--Me at a Cu2/peptide molar ratio of 1:1 (e) in PBS, pH 7.4, at
120 K. Spectrometer and settings were as follows: Bruker ECS106, 9.71 GHz, microwave
power 5.05 milliwatts, modulation frequency 100 kHz, modulation amplitude 5.0 G,
receiver gain 5 105, scan time 84 s, time constant 40 ms, nine scans.
FIGURE 3. Half-field (g 4) EPR spectrum of A 1-28 at a Cu2/peptide molar ratio
0.6:1. Spectra where acquired in PBS, pH 7.4, at 120 K, showing resonance at g  4.
Spectrometer and settingswere as follows: Bruker ESP380E,microwave frequency 9.424
GHz, microwave power 26.4 milliwatts, modulation frequency 100 kHz, modulation
amplitude 5.0 G, receiver gain 1 105, scan time 84 s, time constant 40ms, 26 scans. The
spectrumwasbase line-correctedby subtraction of a spectrumobtainedunder identical
conditions of a quartz tube from the same batch containing PBS, pH 7.4. Broken line,
SOPHE simulation (20) of the spectrum. Spin-Hamiltonian parameters are given in sup-
plementary Table 1. A simulation, using the same spin-Hamiltonian parameters butwith
a smaller linewidth in order to delineate the positions of the Cu2hyperfine resonances,
is shown in supplemental Fig. 1.
A-Cu2-mediated Toxicity Requires a His Bridge
15148 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 22•JUNE 2, 2006
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
where themagnetic spin quantum numberM changes by 1 (
M1),
occur near g 2, whereas “forbidden” or “half-field” transitions, where

M  2, occur near g  4. Thus, the broad line at g  2 and the
resonance at g  4 are diagnostic for a pair of Cu2 ions coupled by
exchange and/or dipolar interactions. Provided that second order
exchange is negligible, the zero field splitting of the triplet state is due to
dipolar interactions alone, and its magnitude depends on 1/R3, where R
is the internuclear distance. The distance between the Cu2 ions can be
calculated from the zero field splitting of the triplet state and can be
estimated by the use of computer simulations.
The measurements at 2.5 K show that antiferromagnetic exchange
interactions are		10 cm1 and therefore that the effect of second order
exchange on the zero field splitting of the triplet state can be neglected.
The broken line spectra shown in Figs. 2 and 3were simulated, assuming
that the zero field splitting of the triplet state is due to dipolar coupling
alone. The parameters giving the best fits are listed in supplemental
Table 1. The fits were obtained by successively varying the geometrical
and spin Hamiltonian parameters and line widths until agreement
between the field positions of peaks in the experimental and computed
spectra was within 10 G. Differences between simulated and experi-
mental spectra are due to linewidth variations, and in the case of the g
2 spectra to there being an equilibrium between different Cu2-bound
states of the peptide, with the simulation representing the predominant
species. The simulation of the g  4 resonance is presented in supple-
mental Fig. 2 with a smaller line width in order tomore clearly delineate
the positions of the Cu2 hyperfine peaks. All fitting attempts con-
verged to the same range of parameters required to fit both the
M 1
and 
M  2 spectra. The values of g  2.34  0.01 and g  2.12 
0.01 are larger than expected for 2- or 3-nitrogen coordination but
indicate that the Cu2 coordination geometry is distorted toward tetra-
hedral (24).
Therefore, the picture that emerges is of one involving two structur-
ally identical Cu2 sites, probably 3N-coordinated, in a tetrahedrally
distorted square planar configuration. The Cu2 ions are 6.2  0.2 Å
apart, with axially symmetric g and Amatrices, but with the symmetry
axes tilted toward the internuclear vector and toward each other by
15 5°. The 6.2 0.2-Å distance between the Cu2 atoms is consistent
with our hypothesis that Cu2 coordination by A at 1:1 Cu2/peptide
occurs via a His bridge between two metal centers to generate a struc-
ture that resembles the active site of superoxide dismutase 1 (25). The
formation of such a bridge is inhibited by themethylation of either of the
nitrogen atoms from the imidazole side chain.
Toxic Properties of A-Cu2 Complexes—To ascertain the possible
physiological significance of the His bridge, A 1-42 (5 M) at Cu2/
peptide molar ratios of 0:1, 0.1:1, 1:1, and 10:1 was tested for neurotoxic
activity on mouse primary cortical cultures (Fig. 4a). Only A 1-42
prepared at a Cu2/peptide molar ratio of 1:1 and 10:1 showed neuro-
toxicity at 5 M, with the 1:1 ratio the most toxic. Toxicity was rescued
by the addition of the H2O2 scavenging enzyme catalase, indicating that
production of ROS is a plausible toxic insult. It therefore appears that
conditions leading to the formation of His-bridged A oligomers are
associated with metal ion-mediated toxicity.
It has previously been shown that metal-free forms of the similarly
methylatedA 1-40 peptide are nontoxic (4). To investigate the effect of
the loss of the His bridge on the toxicity of the metal-bound form of the
A peptide, WT A 1-42, His--Me, and His--Me were added to
mouse primary cortical cultures at Cu2/peptidemolar ratios of 0:1 and
1:1 (Fig. 4b). Under these conditions, theWTA 1-42 at aCu2/peptide
molar ratio of 1:1 reduced cell viability to 70% as compared with the
vehicle. In contrast, both His--Me and His--Me were not toxic. The
EPR data show that no His bridge was induced by Cu2 in either His-
-Me or His--Me at Cu2/peptide molar ratios of1:1. The ability of
the A peptide to induce toxicity therefore correlates with the forma-
tion of the His-bridged dimers of A as observed by EPR.
Cu2Modulation of A Amyloid Formation—Our data suggest that
the ability of A 1-42 to form a His-bridged Cu2-induced dimer was
required for metal-mediated toxicity. In order to determine if there is a
correlation between the ability of the peptides to form amyloid material
FIGURE 4. Toxicity of WT A 1-42 and variant
peptides coordinated to Cu2. Primary cortical
neurons were grown at low density (1.25  105
cells/cm2) for 5days, and the viability of these cells
following peptide treatment was determined by
measuring the inhibition of MTS reduction. Corti-
cal neurons were treated with 5 M peptide for
96 h in serum-freemedia. a, WT A 1-42 at a range
of Cu2/peptide molar ratios (), vehicle control
(f), WT A 1-42 at a range of Cu2/peptidemolar
ratios plus catalase (u). b, WT A 1-42, His--Me,
and His--Me at a final concentration of 5 M at
Cu2/peptide molar ratios of 0:1 (o) and 1:1 ().
Data are shown asmean S.E. Statistical compar-
isons between groups were done using Student’s
t test. p 	 0.05 versus vehicle; each experiment
was carried out in triplicate.
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and this toxic species, WT A 1-42, His--Me, and His--Me were
incubated at 37 °C for 2 h at Cu2/peptide molar ratios of 0:1 to 25:1.
The amyloid content was assessed by use of ThT fluorescence, and the
morphology was assessed by electron microscopy. In the absence of
added Cu2, all peptides showed an increase in ThT fluorescence, indi-
cating the formation of amyloid material (Fig. 5). Comparable ThT
intensities and peptide aggregate morphologies where observed after
24 h of incubation (data not shown). It is interesting to note that His-
-Me produced a 2-fold increase in ThT signal over bothWT A 1-42
and His--Me. This increase in signal may be due to subtle changes in
the morphology of the fibril leading to a greater binding capacity for
ThT or an increase in the total amount of amyloidmaterial. As theCu2
concentration was raised, all three peptides displayed a loss in amyloi-
dogenic material, evident as a decrease in ThT fluorescence. The Cu2-
induced shifts in the aggregation profile from amyloidmaterial to amor-
phous aggregates centered close to a Cu2/peptide molar ratio of 1:1
and were evident for all three peptides. Electron microscopy morpho-
logical analysis of all aggregates (data not shown) demonstrated that the
decrease in ThT signal corresponded to a loss in fibrillar material and a
gain in amorphous aggregate material ranging in size from 10 nm to 1
m.His--Me does display a small amount of ThT fluorescence even in
the presence of high Cu2 concentration (Fig. 5), and concurrently
small fibrillar-like aggregates were observed by electron microscopy
(data not shown). Nevertheless, all three peptides displayed a loss in
amyloid material as the Cu2 concentration rose, and it appears that
Cu2-induced aggregation of A is not dependent on the ability of the
peptide to form a His bridge but on its ability to coordinate the initial
Cu2. It is also clear that conditions promoting the formation of amy-
loid material do not lead to metal ion-mediated toxicity. CD spectra
were recorded for all peptides to determine whether the modifications
significantly altered the structural properties of the peptide in the pres-
ence and absence of Cu2. All three unaged peptides formed -sheet
structures in the presence of Cu2, with the two modified peptides
having a greater-sheet propensity than theWTpeptide (supplemental
Fig. 3).
Cu2 Modulation of A Lipid Interactions—Previous work by our
group (4, 21, 26) and others (13–17) has indicated that the primary toxic
mechanism of A requires an interaction with the plasmamembrane of
cells. In order to assess the ability of A 1-42 and the variant peptides to
penetrate the lipid membrane, the change in fluidity of the acyl-chain
region of LUVswasmonitored by the anisotropy ofDPH.DPH is known
to intercalate axially to the acyl-chain region of a lipid bilayer, and it
reports on the flexibility of this hydrophobic environment (27). Both
aged and unaged WT A 1-42 at Cu2/peptide molar ratios of 0:1 and
1:1, corresponding to the absence or presence of the His bridge, were
allowed to associate with LUVs composed of 50% PC and 50% PS. The
steady-state anisotropy of DPHwas thenmeasured after 20min of incu-
bation (Fig. 6). When unagedWTA 1-42 was allowed to interact with
the lipid membrane, there was little change in the fluidity of the acyl-
chain region over buffer alone (Fig. 6a). However, upon aging for 24 h,
which resulted in the formation of amyloid material, there was a large
decrease in the fluidity of the acyl-chain region as observed by the
increase in anisotropy, representing a perturbation of the membrane
bilayer by the amyloidogenic material. The nonamyloidogenic Cu2
aggregates produced at a Cu2/peptide ratio of 1:1 did not by contrast
perturb this region of the bilayer. A similar pattern of lipid perturbation
was observed with His--Me andHis--Me, where only the presence of
amyloid material leads to a perturbation of the acyl-chain region of the
membrane. It is notable that Cu2 aggregates created by each of the
variant peptides do not lead to a change in the fluidity of the acyl-chain
region of the membrane. Whereas the magnitude of the fluorescence
signal of DPH was slightly quenched by Cu2 (	10–15%), the anisot-
ropy of the fluorophore was not affected by the presence of the metal
ion, since the signal recorded in buffer only is identical in the presence
or absence of additional Cu2 ions. Also, because anisotropy is a ratio of
the intensity of the polarized light to the total light, it varies onlywith the
motility of the fluorophore. These observations would suggest that
mechanical interference of the acyl-chain region of the lipid mem-
brane by the A 1-42 peptide does not contribute to metal ion-
mediated toxicity.
To ascertain if A andA-Cu2 complexes were interacting with the
head group region of the lipidmembrane, experiments were carried out
by 31P magic angle spinning solid-state NMR. The 31P solid-state NMR
spectra of the phospholipid head group of the LUV showed a broad
FIGURE 5.Aggregation properties of A 1-42 at various Cu2/peptidemolar ratios.
Shown is amyloid formation by WT A 1-42 (●), His--Me (‚), and His--Me (u), as a
function of Cu2 concentration, as monitored by ThT fluorescence. 10M samples were
aged at 37 °C for 2 h with agitation at 200 rpm. The experiment was repeated on three
occasions, showing similar results.
FIGURE 6. Perturbation of the acyl-chain region
of a lipid bilayer by A 1-42. Shown is the effect
of WT A 1-42, His--Me, and His--Me at Cu2/
peptide molar ratios of 0:1 and 1:1, for both
unaged (f) and aged peptide () and buffer
alone (u) on the anisotropy (r) of DPH in synthetic
LUVs (50%PC, 50%PS). Data are shownasmean
S.E.; each experiment was carried out in triplicate.
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resonance at 0.75 ppm (Fig. 7a, arrow 2); the addition of A 1-42
resulted in the appearance of a new resonance at 2.51 ppm (Fig. 7b,
arrow 3). The appearance of the second peak indicated the formation of
a lipid-peptide-associated phase. When A 1-42-coordinating Cu2
was added to LUV, the A 1-42-associated lipid signal was reduced
significantly and broadened (Fig. 7c), consistent with the paramagnetic
Cu2 being bound to A 1-42 and in close association with the phos-
pholipid head group. The Cu2 bound to A 1-42 caused paramagnetic
relaxation of the peptide-bound peak andT2 broadening of peaks due to
both PC and PS lipids. This indicated that the Cu2 was interacting
preferentially with the A-phospholipid associated phase rather than
the nonassociated phase. This supports our previous cortical cell cul-
ture studies, where lipid-peptide binding appears to be crucial for cell
toxicity and suggests that phospholipid head group interaction plays an
important role in the pathway for neurotoxicity (4, 21, 26, 28). It is also
worth noting that there is a small shift in the peak due to the phosphate
buffer upon the addition of A, from 1.76 to 1.26 ppm, with a further
shift to 1.00 ppm upon the addition of Cu2. Such shifts are consistent
with the concept that the buffer plays a role in determining the structure
of the peptide as outlined above.
Dityrosine Formation Correlates with the Ability to Form aHis Bridge—
Tyr10 is a critical residue in the production of ROS by A (29), and the
resulting formation of dityrosine adducts has been suggested to play a
role in A aggregation and neurotoxicity (22, 29). Dityrosine adducts of
A are formed as a by-product when the peptide is incubated in the
presence of Cu2 and H2O2 (22, 29). The addition of H2O2 strongly
promotes dityrosine cross-linking via the increased production of ROS
(22, 29). The role of the His bridge in the generation of dityrosine
adducts was assessed by assaying the formation of dityrosine byWTA
1-42, His--Me, and His--Me at a Cu2/peptide molar ratio of 1:1 in
the presence of 250mMH2O2 (Fig. 8). In comparison withWTA 1-42,
His--Me and His--Me showed a marked decrease in the ability to
generate dityrosine adducts (Fig. 8). This lack of dityrosine adducts
reflects a loss in the ability to form the His bridge between Cu2 atoms.
Since tyrosine radicals are relatively short lived, it is likely that the for-
mation of a His bridge between two Cu2 atoms bound to two different
A peptides facilitates the covalent cross-linking by two tyrosine radi-
cals to generate a dityrosine moiety. The ability of the A peptides to
form dityrosine adducts (Fig. 8), therefore, correlates with metal-
dependent toxicity, as shown in Fig. 4b.
Cu2 Modulation of A-induced Lipid Peroxidation—Lipid peroxi-
dation is awell establishedmechanismof cellular injury and an indicator
of oxidative stress that has been implicated in the pathogenesis of AD
(15). Peroxidation of unsaturated fatty acids produces lipid peroxides
that are unstable and decompose to form a series of compounds, includ-
ing reactive carbonyl compounds. To assess whether A-Cu2 com-
plexes can oxidize lipid membranes, we have used a colorimetric assay
to monitor the formation of malondialdehyde and 4-hydroxyalkenals,
which are generated by the peroxidation of unsaturated phospholipids.
WTA 1-42, His--Me, and His--Me at Cu2/peptide molar ratios of
0:1 and 1:1 were incubated with 1 mM 50% PC, 50% PS LUVs for 24 h in
the presence of 10 mM ascorbate, which is present to act as a reductant
to initiate redox cycling of the Cu2 (30). Lipids incubated in an oxygen
atmosphere undergo some degree of peroxidation in the presence of
free Cu2 and ascorbate. However, in the presence of WT A 1-42 at a
Cu2/peptide molar ratio of 1:1, there was a significant increase in lipid
peroxidation compared with the vehicle (Fig. 9a). In contrast, lipid per-
oxidation was attenuated by both His--Me and His--Me, consistent
with the lower neurotoxicity displayed by these peptides at the 1:1 ratio.
The metal-attenuating compound clioquinol (CQ) can inhibit A tox-
icity (29) and amyloid deposition in transgenic mice (31). In a small
phase II clinical trial, CQ was efficacious in moderately affected AD
subjects (32). CQ coordinates Cu2 with a ligand/metal stoichiometry
of 2:1 (33), and we show here that it can inhibit the lipid peroxidation
induced by the WT A-Cu2 complex (Fig. 9b).
DISCUSSION
Wehave previously postulated that one consequence ofCu2 coordina-
tionbyA is the formationof aHis bridgebetween twoCu2 atoms (Fig. 1)
(2, 4), a concept that has been challenged (6–8). Our EPR data presented
here and elsewhere (2, 4) provide strong support for the existenceof a 6.2
0.2-Å binuclear Cu2 center, consistent with the occurrence of a His
bridge, atCu2/peptidemolar ratios in the range0.5–1.0:1 forA1–28,A
1-40, and A 1-42 in PBS. The absence of any evidence for Cu2-bridged
dimers at Cu2/peptide molar ratios of 1:1 with the His--Me and His-
-Me establishes the importance of the imidazole side chain in dimer for-
mation. The broad EPR signals reported here have not been reported in a
number of other EPR studies ofA-Cu2 interactions (6–8). This discrep-
ancy is due todifferences in buffer conditions and themodeof presentation
of Cu2 to the A peptide; no two studies have used the same conditions.
FIGURE 7. 31P magic angle spinning NMR spectra of LUV in the presence of WT A
1-42 and Cu2. Spectra were acquired in PBS, pH 7.4. Shown are lipid alone (a), withWT
A 1-42 added at a lipid/peptide ratio of 30:1 (b), andwithWTA 1-42 in the presence of
equimolarCu2at a lipid/peptide ratioof 30:1 (c). Peak labels are as follows.1, phosphate
buffer resonance 1.5 ppm. 2, phospholipid head group of LUV 0.75 ppm. 3, lipid-
peptide-associated phase 2.51 ppm.
FIGURE 8. Formation of dityrosine A adducts. Shown areWT A 1-42, His--Me, and
His--Me. 10 M peptide was incubated at 37 °C with agitation at 200 rpm for 2 h at a
Cu2/peptide molar ratio of 1:1 in the presence of 250 M H2O2. Data are shown as
mean S.E.; each experiment was carried out in triplicate.
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BothHuang et al. (34) andNarayanan andReif (35) have shown that buffer
constituents, such as NaCl, have a marked effect on metal-mediated oli-
gomerization of A. We obtained our spectra in PBS at pH 6.9–7.5 and
presentedCu2 asCuCl2 (2). In contrast, Syme et al. (7) used thenonphysi-
ological ethylmorpholine buffers at pH 7.8 and presented Cu2 as
Cu(NO3)2. When we acquired a Cu2 EPR spectrum at Cu2/peptide
molar ratios of 1:1 in this buffer, we also did not observe line broadening.
We have been careful to distinguish between the broad lines due to either
His-bridged binuclear Cu2 centers or aggregates and the line broadening
of mononuclear spectra that can arise in different ways. Further, the plei-
omorphic nature ofA is well documented, and it is not surprising that the
buffer conditions used will have a profound influence on the observed
structural state.
Whereas the mechanism of A toxicity in AD remains unresolved, a
general theme is beginning to emerge whereby the interaction of A
with lipid membranes is a necessary step in neurotoxicity (13–17).
These interactions result in changes in membrane fluidity leading to
depolarization and disorder (13), pore/channel formation leading to ion
channel formation and disrupted calcium homeostasis (14, 16), lipid
peroxidation via membrane-associated free radical formation (15), and
cholesterol oxidation (17). H2O2 and ROS production has been impli-
cated in the neurotoxicity of A, and the A-Cu2 complexes are able
to produce H2O2 (36–38). The production of H2O2 has been shown to
occur during a short burst at the early stages of aggregation, around the
time soluble oligomers are being produced (39). In this study, we dem-
onstrated that toxicity to primary cortical neurons correlates with the
formation of a His bridge between Cu2 ions, which is populated at
equimolar Cu2/peptide ratios (Figs. 3 and 4). The resulting toxic effect
was rescued by the addition of catalase, implicating H2O2 generation. A
consequence of ROS production is lipid peroxidation, resulting in sub-
FIGURE 9. Lipid peroxidation of synthetic LUVs.
a, 1 mM lipid was incubated with 10 M peptide
and 10M ascorbate at Cu2/peptide ratios of 0:1
() and 1:1 (f) for 24 h at 37 °C. b, 1 mM lipid was
incubated with 10 M WT peptide and 10 mM
ascorbate at Cu2/peptide ratios of 1:1 for 24 h at
37 °C. CQ was added at a final concentration of 2,
20, and 50M inMe2SO. Me2SOwas at a final con-
centration of 1% and accounts for the lower
observed level of lipid peroxidation. Lipid peroxi-
dation was determined via a colorimetric assay
that measures the concentration of peroxidation
by-products malondialdehyde (MDA) and 4-hy-
droxyalkenals (HNE). Data are shown as mean 
S.E. Statistical comparisons between groups were
done using Student’s t test. p 	 0.05 versus vehi-
cle; each experiment was carried out in triplicate.
TABLE 1
Correlation of toxicity with formation of His-bridged structures andmembrane binding
Conditions leading to both His bridge formation and membrane interactions increased the Cu2-mediated neurotoxicity of A peptide and its variants. Membrane
interactions are defined as cellular binding, binding/insertion to synthetic lipids in the presence or absence of cholesterol/lipid peroxidation.
Peptides Toxicity Cu
2 coordination/His bridge
formation Membrane Interactions
Nontoxic A peptides
A 1-28 Slight (43) Yes/Yes (2, 3)a Slight (43, 45)
A 1-40 His--Me No (4) Yes/No (4) No (4)
A 1-40 His--Me No (4) Yes/No (4) No (4)
A 1-42 His--Me No (17)a Yes/Noa Slight (17)a
A 1-42 His--Me No (17)a Yes/Noa No (17)a
A 1-42 Y10A Slight (17, 29) Yes/Unknown (29) Slight (17)
Toxic A peptides
A 1-40 Yes (5, 43) Yes/Yes (4) Yes (43, 45, 46)
A 1-42 Yes (5, 17, 21, 29, 43)a Yes/Yesa Yes (17, 43)a
A 1-42 M35V Enhanced (21) Yes/Unknown (21) Enhanced (21)
A 1-42 Met Ox Yes (26) Yes/Unknown (26) Yes (26)
a Data in this paper.
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sequent cell death, which precedes amyloid plaque formation (15, 40).
Supporting this mechanism, we have demonstrated that A 1-42 at
Cu2/peptidemolar ratios of 1:1, conditions inwhich theHis bridgewas
formed, induced lipid peroxidation (Fig. 9). Interestingly, the observed
toxicity to primary cortical neurons does not correlate with the ability of
the peptides to form amyloid material or to mechanically perturb the
acyl-chain region of a lipid membrane, as monitored by the anisotropy
of DPH (Figs. 5 and 6). Solid-state NMR studies indicate that the A
peptide has an affinity for negatively charged phospholipids (41, 42).
Our previous 31P static solid-state NMR data have also shown that met-
al-bound forms of A increase perturbation of the lipid head groups,
mediated through Cu2 binding, compared with the metal-free form
(28). Here we demonstrate the appearance of a lipid-A-bound phase
and a peptide-free lipid phase (Fig. 7) due to the lipid head group inter-
action with WT A 1-42. The observation of a lipid-A-bound phase
indicated that A and A-Cu2 complexes were able to associate with
the lipid membrane head group region and that this association would
promote lipid peroxidation.
Conditions that lead to the formation of the His-bridged A oli-
gomers result in the population of a highly toxic species. It follows,
therefore, that disruption of this structure would abrogate A toxicity.
In agreementwith this hypothesis, methylation of the threeHis residues
at either the - or -nitrogen of the imidazole side chain resulted in the
elimination of the His bridge at equimolar Cu2/peptide ratios (Figs. 2
and 3). These modifications rendered the peptide nontoxic (Fig. 4);
congruently, a loss in lipid peroxidation activity was observed (Fig. 9a).
That CQ was able to inhibit the observed lipid peroxidation (Fig. 9b) is
consistent with this process being a metal-dependent phenomenon,
since previously observed data have shown that CQ inhibits A/Cu
interactions (31). The loss in toxic activity presumably resulted from the
modified A peptides sequestering the redox-active Cu2 away from
the lipid environment. Tickler et al. (4) have shown previously that
His--Me- and His--Me-modified A peptides have a lower affinity
for lipid membranes, and since ROS are relatively short lived species
that react with substrates in their immediate vicinity, less lipid peroxi-
dation is expected and observed for these peptides.
Moreover, eliminating the His bridge also affected the formation of
dityrosine adducts (Fig. 8). Tyr10 is critical in the redox cycling of Cu2-
associated ROS production byA-Cu2 (29). A by-product of the redox
reactions is that two tyrosine radicals can react to form dityrosine
adducts. The formation of dityrosine adducts by both His--Me and
His--Me A was severely inhibited (Fig. 8), correlating with the
decrease in lipid peroxidation (Fig. 9) and subsequent toxicity (Fig. 4).
This is consistent with a role for either the tyrosine radical or dityrosine
in metal-mediated toxicity.
A survey of the literature shows that variations to the A peptide
sequence that ablate lipid binding cause a decrease in A neurotoxicity
(Table 1). A 1-28, which is capable of binding to lipids, although
weakly, has been reported to show a small degree of toxicity (43). Meth-
ylation of theHis residues at either the- or -nitrogen of the imidazole
side chain of A 1-40/42 results in a loss in lipid binding and toxicity as
well as a loss in the ability to form the His bridge (4). By contrast, A
1-42 containing aM35Vmutation shows an increase in toxicity over the
WT peptide and displays a higher affinity for lipid membranes (21). In
addition, A 1-42with an oxidizedMet35 is unable to penetrate the lipid
membrane but is able to bind to the surface and induce toxicity (26).
These results, together with the data presented here, lead to a model
whereby binding of A to the surface of a lipid membrane is required to
cause Cu2-induced toxicity. Taken with the results presented above,
the toxic A-Cu2 species requires the formation of the His bridge and
imparts its toxic effect via the association with lipids and the generation
of ROS, resulting in lipid peroxidation and subsequent cell death. The
lipid peroxidation can be inhibited by the use of the metal-attenuating
compound CQ, which can disaggregate metal-induced aggregates and
retard fibril growth (44) and inhibit amyloid deposition in transgenic
mice (31) and was efficacious in a phase II clinical trial on a severely
affected AD group (32). Therefore, strategies aimed at inhibiting the
formation of His-bridged A-Cu2 complexes, thereby preventing
metal-induced A oligomer formation and consequent production of
ROS, would limit the oxidative stress associated with AD and be of
therapeutic benefit.
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Supplementary Fig 1 - EPR spectra of Aβ1-28 ethylmorpholine buffer. Spectra where acquired at pH 7.4 at 
120 K (a) Cu2+:peptide molar ratio of 0.5:1, (b) Cu2+:peptide molar ratio of 1:1. Additional components I 
and II previously observed (7) shown by broken lines. Note the proportions of I and II are changed as the 
Cu2+:peptide molar ratio is increased. Spectrometer and settings; Bruker ESP380E, microwave frequency 
9.425 GHz, microwave power 4.18 mW, modulation frequency 100 KHz, modulation amplitude 4.0 G,  
receiver gain 1 x 105, scan time 168 s, time constant 164 ms, single scan. 
 
  
Supplementary Fig 2 - High resolution simulation of half-field resonance. Full line: experimental spectrum 
of Aβ1-28 in the g ~ 4 region as in Figure 3 of main text. Broken line: simulated spectrum using the same 
spin Hamiltonian parameters as for Figure 3, but with a reduced linewidth in order to more clearly delineate 
the positions of the Cu2+ hyperfine peaks. 
 
  
 
Supplementary Fig 3.  CD spectra of Cu2+ being titrated into PBS solutions of (a) WT Aβ1-42 (b) His-π-
Me Aβ1-42 and (c) His-τ-Me Aβ1-42.  All peptides form β-sheet structures upon addition of Cu2+, with the 
modified peptides having a higher tendency than WT Aβ1-42. 
 
 
Supplementary Table 1  
Spin Hamiltonian parameters for simulated spectra shown in Figures 2a- c and Figure 3. Estimated 
uncertainties are given in parentheses. 
 
 
g║ g⊥ 
A║ 
(10-4 cm-1) 
A⊥ 
(10-4 cm-1) 
σ║ 
(10-4 cm-1) 
σ⊥ 
(10-4 cm-1) 
Aβ1-28 mononuclear 
Cu2+ a 
 
2.28 ± 
0.01 
2.06 ± 
0.01 
175 ± 5 5 ± 5 50 ± 10 40 ± 10 
Aβ1-28 binuclear Cu2+ 
centre b 
 
2.340 ± 
0.01 
2.12 ± 
0.01 
150 ± 5 5 ± 5 40 ± 5 40 ± 50 
Aβ1-28  
Cu2+ aggregate c 
2.14 ± 0.01 60 ± 10 120 ± 20 
 
Notes 
 
a Figure 2a 
b Figure 2b and Figure 3. R (distance between Cu2+ ions) 6.2 ± 0.2 Å; z axes of g and A of individual ions 
tilted towards each other and along the internuclear vector by 15 ± 5°. The linewidth quoted is for the g ~ 2 
spectrum. The g ~ 4 spectrum shown in Figure 3 was simulated with a linewidth of 70 x 10-4 cm-1, while 
that of Supplementary Figure 1 was simulated with a linewidth of 35 x 10-4 cm-1. 
c  Figure 2c. The simulation is indicative only. Note that the values of g and A used in the simulation 
approximate the average of the parameters used to simulate the mononuclear spectrum. 
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